EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access

[Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas

Jana Ivanidze iD, Se Jung Chang, Arsalan Haghdel, Joon Tae Kim, Arindam Roy Choudhury, Alan Wu, Rohan Ramakrishna iD, Theodore H Schwartz, Babacar Cisse, Philip Stieg, Leland Muller, Joseph R Osborne und 7 weitere

Neuro-Oncology · 05.08.2024 · 26 (8) · 1526-1535

DOI: 10.1093/neuonc/noae067 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Neuro-Oncology, online erschienen am 30.03.2024. Verfasst von Jana Ivanidze und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Meningeal Neoplasms, Meningioma, Organometallic Compounds. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Varian Medical Systems, GE Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Our purpose was to determine the utility of [68Ga]-DOTATATE PET/MRI in meningioma response assessment following radiosurgery.

Methods

Patients with meningioma prospectively underwent postoperative DOTATATE PET/MRI. Co-registered PET and gadolinium-enhanced T1-weighted MRI were employed for radiosurgery planning. Follow-up DOTATATE PET/MRI was performed at 6–12 months post-radiosurgery. Maximum absolute standardized uptake value (SUV) and SUV ratio (SUVRSSS) referencing superior sagittal sinus (SSS) blood pool were obtained. Size change was determined by Response Assessment in Neuro-Oncology (RANO) criteria. Association of SUVRSSS change magnitude and progression-free survival (PFS) was evaluated using Cox regression.

Results

Twenty-seven patients with 64 tumors (26% World Health Organization [WHO]-1, 41% WHO-2, 26% WHO-3, and 7% WHO-unknown) were prospectively followed post stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT; mean dose: 30 Gy, modal dose 35 Gy, mean of 5 fractions). Post-irradiation SUV and SUVRSSS decreased by 37.4% and 44.4%, respectively (P < .0001). Size product decreased by 8.9%, thus failing to reach the 25% significance threshold as determined by RANO guidelines. Mean follow-up time was 26 months (range: 6–44). Overall mean PFS was 83% and 100%/100%/54% in WHO-1/-2/-3 subcohorts, respectively, at 34 months. At maximum follow-up (42–44 months), PFS was 100%/83%/54% in WHO-1/-2/-3 subcohorts, respectively. Cox regression analyses revealed a hazard ratio of 0.48 for 10-unit reduction in SUVRSSS in the SRS cohort.

Conclusions

DOTATATE PET SUV and SUVRSSS demonstrated marked, significant decrease post-radiosurgery. Lesion size decrease was statistically significant; however, it was not clinically significant by RANO criteria. DOTATATE PET/MR thus represents a promising imaging biomarker for response assessment in meningiomas treated with radiosurgery. ClinicalTrials.gov Identifier NCT04081701

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingMeningeal NeoplasmsMeningiomaOrganometallic CompoundsPositron-Emission TomographyRadiosurgeryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFollow-Up StudiesMultimodal ImagingPrognosisProspective StudiesRadiopharmaceuticalsRadiotherapy Planning, Computer-Assisted

Stichwörter der Autor:innen

DOTATATEPET/MRImeningiomaoutcomesradiosurgery

Substanzen

gallium Ga 68 dotatateOrganometallic CompoundsRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
  • Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA.
  • Department of Neurological Surgery, Weill Cornell Medicine, New York, New York, USA.
  • Department of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA.
  • Brain Tumor Center, Weill Cornell Medicine, New York, New York, USA.
  • Department of Radiation Oncology, Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Jana Ivanidze, Rohan Ramakrishna, Joshua D Palmer

Förderung

  • Varian Medical Systems
  • GE Healthcare

Zitieren

APA

Ivanidze, J., Chang, S. J., Haghdel, A., Kim, J. T., Roy Choudhury, A., Wu, A., Ramakrishna, R., Schwartz, T. H., Cisse, B., Stieg, P., Muller, L., Osborne, J. R., Magge, R. S., Karakatsanis, N. A., Roytman, M., Lin, E., Pannullo, S. C., Palmer, J. D., & Knisely, J. P. S. (2024). [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas. Neuro-Oncology, 26(8), 1526-1535. https://doi.org/10.1093/neuonc/noae067

Vancouver

Ivanidze J, Chang SJ, Haghdel A, Kim JT, Roy Choudhury A, Wu A, et al. [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas. Neuro-Oncology. 2024;26(8):1526-1535. doi:10.1093/neuonc/noae067

BibTeX
@article{Ivanidze2024,
  author = {Ivanidze, Jana and Chang, Se Jung and Haghdel, Arsalan and Kim, Joon Tae and Roy Choudhury, Arindam and Wu, Alan and Ramakrishna, Rohan and Schwartz, Theodore H and Cisse, Babacar and Stieg, Philip and Muller, Leland and Osborne, Joseph R and Magge, Rajiv S and Karakatsanis, Nicolas A and Roytman, Michelle and Lin, Eaton and Pannullo, Susan C and Palmer, Joshua D and Knisely, Jonathan P S},
  title = {[Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {8},
  pages = {1526--1535},
  doi = {10.1093/neuonc/noae067}
}
Kostenlos starten →